GlassScriptPhysician profile
Jennifer E Atwater
NPI 1568642874
$1,094.32
in general payments reported to CMS, 2019-2025
19 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.92 · 2022: $212 · 2023: $128 · 2024: $385 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.79 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $339.84 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $277.50 | 2022-2025 | Zepbound, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $83.50 | 2024-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $66.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $37.65 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $29.81 | 2024-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $29.34 | 2023-2024 | |
| Glaxosmithkline, LLC. | $29.15 | 2024 | Trelegy Ellipta |
| Lundbeck LLC | $25.26 | 2025 | Rexulti |
| Eisai INC. | $24.74 | 2025 | |
| Cipher Pharmaceuticals US LLC | $21.75 | 2025 | Spinosad, Natroba |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.83 | 2024 | Xifaxan, Trulance |
| Tolmar, INC. | $19.48 | 2024 | |
| Abbvie INC. | $18.08 | 2022 | |
| Merck Sharp & Dohme LLC | $17.83 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $15.13 | 2024 | Qelbree |
| Idorsia Pharmaceuticals US INC | $13.79 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $13.30 | 2022 | |
| Phathom Pharmaceuticals, INC. | $12.04 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Atwater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.